Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-53408 in Adults With Celiac Disease
NCT06807463Phase 2Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of TEV-53408 in celiac disease, sponsored by Teva Pharmaceutical Industries Ltd.. Started Mar 2025; status: active, not recruiting.
02
Drugs
TEV-53408
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT06807463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06807463.